Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Capital Expenditures (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Capital Expenditures for 17 consecutive years, with $4.7 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 30.56% to $4.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.6 million through Dec 2025, down 17.89% year-over-year, with the annual reading at $15.6 million for FY2025, 17.89% down from the prior year.
  • Capital Expenditures for Q4 2025 was $4.7 million at Myriad Genetics, up from $2.8 million in the prior quarter.
  • The five-year high for Capital Expenditures was $53.2 million in Q3 2023, with the low at -$14.6 million in Q4 2021.
  • Average Capital Expenditures over 5 years is $5.8 million, with a median of $4.7 million recorded in 2025.
  • The sharpest move saw Capital Expenditures tumbled 533.33% in 2022, then surged 509.23% in 2023.
  • Over 5 years, Capital Expenditures stood at -$14.6 million in 2021, then grew by 10.96% to -$13.0 million in 2022, then skyrocketed by 176.92% to $10.0 million in 2023, then plummeted by 64.0% to $3.6 million in 2024, then surged by 30.56% to $4.7 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $4.7 million, $2.8 million, and $2.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.